We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Actividentity Corp (MM) | NASDAQ:ACTI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.24 | 0 | 01:00:00 |
Please see the attached notification, which is being announced within short in Svenska Dagbladet and Post- och Inrikes Tidningar.
Lund, May 12, 2015ACTIVE BIOTECH AB (PUBL)THE BOARD OF DIRECTORS
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal phase III development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in phase II development for the treatment of primary progressive multiple sclerosis and Huntington's disease. The project portfolio includes a preclinical project, ISI, with the objective to produce new, patentable chemical compounds for treatment of diseases within the company's focus areas. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)Box 724, SE-220 07 LundTel: +46 46 19 20 00 Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on May 12, 2015.
Notice of Annual General Meeting of Shareholders http://hugin.info/1002/R/1920502/688008.pdf
HUG#1920502
1 Year Actividentity Corp (MM) Chart |
1 Month Actividentity Corp (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions